Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the combination of camizestrant and ribociclib in patients with estrogen receptor-positive ER, human epidermal growth factor receptor 2-negative HER2- advanced breast cancer who have not previously received systemic treatment for their advanced disease. This Phase IIIb, global, multicenter, single-arm study aims to assess the effectiveness, safety, and tolerability of this treatment approach. Participants will receive daily oral doses of camizestrant at 75 mg and ribociclib at 600 mg. All enrolled patients will take these medications until they decide to stop treatment or for any other reason that leads to discontinuation. The study does not involve comparison groups but monitors treatment outcomes in all participants receiving the combination. During the study, participants will undergo evaluations to monitor how long they remain on treatment before starting another therapy or experiencing progression. Researchers will assess treatment safety, including any significant side effects occurring within the first six months. Participants will have regular visits to assess their health status and treatment response. The total study duration extends up to two years following the first dose of treatment.
Actively Recruiting
Researchers are evaluating the effect of preoperative oral immunonutrition IN on reducing post-operative complications in patients undergoing cystectomy, a surgery to remove the bladder. This multicenter randomized controlled trial aims to assess whether IN can improve outcomes like infections after surgery and to develop a method to identify patients who would benefit most from this nutrition. The study addresses the high complication rates associated with cystectomy and the role of malnutrition as a risk factor. Participants are randomly assigned to one of two groups one receives seven days of oral immunonutrition before surgery, and the other follows standard care without IN. The immunonutrition supplement, Oral Impact, is taken three times daily for seven days before the operation. The trial compares these approaches to see if preoperative IN reduces complications and improves immune response. During the study, researchers will monitor infectious complications within 30 days after surgery as the primary outcome. Secondary outcomes include overall complication rates at 30 and 90 days, mortality rates, complication-free survival, and treatment compliance. Participants will be assessed through clinical evaluations and compliance tracking from 30 days before surgery through hospital admission. The total participation duration varies depending on surgery timing and follow-up assessments.